Nucleus Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 17-11-2024
- Paid Up Capital ₹ 1.50 M
as on 17-11-2024
- Company Age 14 Year, 23 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 6.29 M
as on 17-11-2024
- Revenue 12.63%
(FY 2023)
- Profit -35.03%
(FY 2023)
- Ebitda -27.77%
(FY 2023)
- Net Worth 3.61%
(FY 2023)
- Total Assets -13.21%
(FY 2023)
About Nucleus Biosciences
The Corporate was formerly known as Walpar Healthcare Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company has closed loans amounting to ₹6.29 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Himanshu Patel and Vishal Parmar serve as directors at the Company.
- CIN/LLPIN
U24230GJ2011PTC063498
- Company No.
063498
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jan 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nucleus Biosciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vishal Parmar  | Director | 05-Jan-2011 | Current |
| Himanshu Patel | Director | 05-Jan-2011 | Current |
Financial Performance of Nucleus Biosciences.
Nucleus Biosciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.63% increase. The company also saw a substantial fall in profitability, with a 35.03% decrease in profit. The company's net worth moved up by a moderate rise of 3.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nucleus Biosciences?
In 2022, Nucleus Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹0
₹6.29 M
Charges Breakdown by Lending Institutions
- Bank Of Baroda : 0.63 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Jun 2013 | Bank Of Baroda | ₹6.29 M | Satisfied |
How Many Employees Work at Nucleus Biosciences?
Unlock and access historical data on people associated with Nucleus Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nucleus Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucleus Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
